For full functionality of this website it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser

Session Details

Revolutionizing Patient Access: Disrupting the Delivery of Cell and Gene Therapies
Wednesday, May 29, 2024 08:00 AM - 09:00 AM  
Room 217-219
Bioprocessing & Manufacturing
Roundtable
Organized by: ISCT Industry Committee

Moderator(s)   
  • Julie Allickson, Ph.D, Mayo Clinic Center for Regenerative Biotherapeutics & Biomanufacturing and Product Development, Center for Regenerative Biotherapeutics and Associate Professor of Regenerative Medicine., United States
 
Panelists
  • Boro Dropulic, PhD, Caring Cross, United States
  • Jennifer Chow, Chimeric Therapeutics, United States
  • Kimberly Schultz, PhD, Food and Drug Administration (FDA), United States

Debate the merits and disadvantages of centralized manufacturing, regional processing, and point of care manufacturing.

Key Learning Objectives 
1. What are the issues regarding patient access to CAR-T therapies
2. What are the various scenarios that are being explored
3. Where should therapeutic and tool developers focus their efforts in this space

 

Kimberly Schultz
Director, Division 2 in the Office of Gene Therapy
US FDA
Panelist


Julie Allickson
Director of Mayo Clinic's Center for Regenerative Biotherapeutics
Mayo Clinic
Moderator


Jennifer Chow
CEO and Managing Director
Chimeric Therapeutics Limited
Panelist


Boro Dropulic
CEO
Vector BioMed
Panelist